Global Pharmacogenomics Market Size Worth USD 11.17 Billion by 2033, Exhibiting a CAGR of 6.6%

Pharmacogenomics Market Outlook

According to Straits Research, the global pharmacogenomics (pgx) market size was estimated at USD 6.13 billion in 2024 and is projected to grow from USD 6.69 billion in 2025 to USD 11.17 billion by 2033, exhibiting a CAGR of 6.6% during the forecast period 2025 to 2033.

Pharmacogenomics is a wide field comprising the study of the genome's reaction to drugs, combining the fields of pharmacology and genomics. It helps to understand how individual genetic differences influence drug efficacy and the adverse events. The major factor propelling the growth of the market is growing focus on precision medicine and personalized therapeutics, increasing incidences of adverse drug reactions, and growing direct-to-consumer genetic testing. Further, the development of multi-gene pharmacogenomics panels and increasing integration in oncology for targeted therapies present significant opportunities in the market.

Download the Sample Pages of this Report for Better Understanding @ https://straitsresearch.com/report/pharmacogenomics-market/request-sample

Key Highlights:

Based on type, the market is segmented into products, services and software. The product segment accounted for a major pharmacogenomics market share, owing to its broad adoption in clinical workflows for genotype-based drug response testing.

Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, mass spectrometry, microarray and others. The polymerase chain reaction segment dominated the pharmacogenomics sector in 2024. This growth is driven by its cost-effectiveness, rapid results, and widespread use in gene variant detection.

Based on application, the market is segmented into cardiovascular disease, infectious diseases, oncology, neurological diseases, pain management and trauma and others. The oncology segment dominated the pharmacogenomics sector with a market share of 37.9%. This growth is driven by its increasing cancer incidence and demand for precision therapies like targeted and immunotherapies.

Based on end user, the market is segmented into hospitals, clinical laboratories, pharmaceutical companies, academic research institutions and others. The clinical laboratories segment is expected to grow at the fastest CAGR, due to expansion of decentralized and rapid genetic testing services.

Market Dynamics

Clinical pharmacogenomic guidelines expansion drives the demand for pharmacogenomics

The expansion of clinical pharmacogenomic guidelines is a major driver of the pharmacogenomics market, enabling standardized, evidence-based integration of genetic data into clinical practice. Organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have been pivotal in publishing actionable, peer-reviewed guidelines that link genetic variants to drug responses.

As of 2024, CPIC has released over 40 gene-drug guidelines, covering critical areas such as antidepressants, cardiovascular drugs, and oncology therapies.

A study published in The Lancet Digital Health in 2023 found that 71% of U.S. healthcare systems implementing pharmacogenomics rely on CPIC guidelines, highlighting their clinical influence.

Thus, the increasing number of such guidelines encourages more hospitals and healthcare providers to adopt pharmacogenomic testing, thereby accelerating market growth and supporting the clinical utility of pharmacogenomics worldwide.

To Visit Here For Grab More Insights @ https://straitsresearch.com/report/pharmacogenomics-market

Partnerships between hospitals and genomics labs: Key market opportunity

Strategic partnerships between hospitals and genomics laboratories present a significant opportunity in the pharmacogenomics market by facilitating faster adoption of personalized medicine. These collaborations help integrate pharmacogenomic testing directly into clinical workflows, improving turnaround times and enhancing clinical decision-making. Hospitals benefit from the technological expertise and infrastructure of genomics labs, while labs gain access to real-world patient data and sample volumes.

For example, in January 2023, Mayo Clinic partnered with Helix, a genomics company, to expand population-scale pharmacogenomic screening within its healthcare system.

Additionally, according to the National Academy of Medicine, such collaborations have led to a significant increase in pharmacogenomic test adoption in partner hospitals across the U.S.

Such partnerships accelerate the creation of localized gene-drug databases, making therapies safer and more effective. As the demand for tailored treatment grows, hospital-lab alliances are expected to play a vital role in expanding access to actionable genomic insights.

List of key players in the Pharmacogenomics (PGX) Market

QIAGEN, Illumina, Inc., Agilent Technologies, Inc., Foundation Medicine, Inc., Thermo Fisher Scientific Inc., Admera Health, Myriad Genetics, Inc., Beckman Coulter, Inc., OneOme, Genomind, Coriell Life Sciences, PGxAI, Tempus, DEEP GENOMICS, Helix, Inc. and Oxford Nanopore Technologies plc., and others.

Market Segmentation Analysis

By Type
Products
Services
Software

By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
Microarray
Others

By Application
Cardiovascular disease
Infectious diseases
Oncology
Neurological diseases
Pain Management and Trauma
Others

By End-User
Hospitals
Clinical Laboratories
Pharmaceutical Companies
Academic Research Institutions
Others

Get Detailed Market Segmentation @ https://straitsresearch.com/report/pharmacogenomics-market/segmentation

Regional Insights

North America accounted for the major share of 37.6% in pharmacogenomics, owing to strong healthcare infrastructure, well-established reimbursement schemes, and increasing incidences of adverse reactions. The region benefits from a high concentration of key market players, extensive research funding, and integration of pharmacogenomic data into electronic health records (EHRs).

Additionally, initiatives such as the U.S. FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling and the NIH's All of Us Research Program have accelerated clinical adoption. Favorable reimbursement policies and the presence of leading diagnostic labs further contribute to North America's dominant position in the global market.

The Asia Pacific region is anticipated to grow at the fastest CAGR during the forecast period. This growth is driven by increasing investments in genomic research, expanding healthcare infrastructure, and a rising focus on precision medicine across emerging economies. Countries such as China, Japan, South Korea, and India have launched national genome initiatives to map genetic diversity and enhance personalized treatment, encouraging the adoption of pharmacogenomics across the region.

Recent Developments

In May 2025, Helix, Inc., announced the launch of a new suite of pharmacogenomics tests, including a test designed to identify patients with DYPD gene variants who may be at increased risk for side effects from certain chemotherapies, as well as a first-of-its-kind test that assesses APOE status relevant to newly available Alzheimer's drugs.

In May 2024, Oxford Nanopore Technologies plc. collaborates with Twist Bioscience to launch the Pharmacogenomics Beta Programme and advance personalised medicine.

Inquiry Before Buying @ https://straitsresearch.com/buy-now/pharmacogenomics-market

Top Related Reports:

Genome Sequencing Market Size: https://straitsresearch.com/report/genome-sequencing-market

Genome Editing Market Size: https://straitsresearch.com/report/genome-editing-market

Optical Genome Mapping Market: https://straitsresearch.com/report/optical-genome-mapping-market

Genotyping Market Size: https://straitsresearch.com/report/genotyping-market

Genome Sequencing Market Size: https://straitsresearch.com/report/genome-sequencing-market

Next Generation Sequencing Market Size: https://straitsresearch.com/report/next-generation-sequencing-market

Metagenomic Sequencing Market Size: https://straitsresearch.com/report/metagenomic-sequencing-market

Contact Us:

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/

About Us:

StraitsResearch.com is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services, along with providing business insights & market research reports.

This release was published on openPR.